Apolipoprotein E4 interferes with lipid metabolism to exacerbate depression-like behaviors in 5xFAD mice

Abstract

Background: Apolipoprotein E4 (ApoE4) allele is the strongest genetic risk factor for late-onset Alzheimer’s disease, and it can aggravate depressive symptoms in non-AD patients. However, the impact of ApoE4 on AD-associated depression-like behaviors and its underlying pathogenic mechanisms remain unclear.

Methods: This study developed a 5xFAD mouse model overexpressing human ApoE4 (E4FAD). Behavioral assessments and synaptic function tests were conducted to explore the effects of ApoE4 on cognition and depression in 5xFAD mice. Changes in peripheral and central lipid metabolism, as well as the levels of serotonin (5-HT) and γ-aminobutyric acid (GABA) neurotransmitters in the prefrontal cortex, were examined. In addition, the protein levels of 24-dehydrocholesterol reductase/glycogen synthase kinase-3 beta/mammalian target of rapamycin (DHCR24/GSK3β/mTOR) and postsynaptic density protein 95/calmodulin-dependent protein kinase II/brain-derived neurotrophic factor (PSD95/CaMK-II/BDNF) were measured to investigate the molecular mechanism underlying the effects of ApoE4 on AD mice.

Results: Compared with 5xFAD mice, E4FAD mice exhibited more severe depression-like behaviors and cognitive impairments. These mice also exhibited increased amyloid-beta deposition in the hippocampus, increased astrocyte numbers, and decreased expression of depression-related neurotransmitters 5-HT and GABA in the prefrontal cortex. Furthermore, lipid metabolism disorders were observed in E4FAD, manifesting as elevated low-density lipoprotein cholesterol and reduced high-density lipoprotein cholesterol in peripheral blood, decreased cholesterol level in the prefrontal cortex, and reduced expression of key enzymes and proteins related to cholesterol synthesis and homeostasis. Abnormal expression of proteins related to the DHCR24/GSK3β/mTOR and PSD95/CaMK-II/BDNF pathways was also observed.

Conclusion: This study found that ApoE4 overexpression exacerbates depression-like behaviors in 5xFAD mice and confirmed that ApoE4 reduces cognitive function in these mice. The mechanism may involve the induction of central and peripheral lipid metabolism disorders. Therefore, modulating ApoE expression or function to restore cellular lipid homeostasis may be a promising therapeutic target for AD comorbid with depression. This study also provided a better animal model for studying AD comorbid with depression.

Keywords

5xFAD mice / Alzheimer’s disease / ApoE4 allele / depression like

References

[1] Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708-3821.

[2] Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement. 2023;19(2):658-670.

[3] Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339.

[4] Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553-1560.

[5] Ahmed Z, Cooper J, Murray TK, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127(5):667-683.

[6] Martin-Sanchez A, Pinero J, Nonell L, et al. Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice. Alzheimers Res Ther. 2021;13(1):73.

[7] Tetreault AM, Phan T, Orlando D, et al. Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer’s disease. Brain. 2020;143(4):1249-1260.

[8] Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532-539.

[9] Chen Y, Dang M, Zhang Z. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and -specific lesion patterns. Mol Neurodegener. 2021;16(1):38.

[10] Liu CC, Zhao J, Fu Y, et al. Peripheral ApoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nat Neurosci. 2022;25(8):1020-1033.

[11] Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County dementia progression study. Am J Psychiatry. 2015;172(5):460-465.

[12] Yang HS. Human genetics clarifies the relationship between depression and Alzheimer’s disease. Biol Psychiatry. 2022;92(1):2-4.

[13] Bai X, Mai M, Yao K, et al. The role of DHCR24 in the pathogenesis of AD: re-cognition of the relationship between cholesterol and AD pathogenesis. Acta Neuropathol Commun. 2022;10(1):35.

[14] Huang S, Zhang Z, Cao J, Yu Y, Pei G. Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer’s tau pathology. Signal Transduct Target Ther. 2022;7(1):176.

[15] Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024;25(2):91-110.

[16] Martens YA, Zhao N, Liu CC, et al. ApoE Cascade hypothesis in the pathogenesis of Alzheimer’s disease and related dementias. Neuron. 2022;110(8):1304-1317.

[17] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577-1590.

[18] Blanchard JW, Akay LA, Davila-Velderrain J, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611(7937):769-779.

[19] Tcw J, Qian L, Pipalia NH, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell. 2022;185(13):2213-2233.

[20] van der Kant R, Langness VF, Herrera CM, et al. Cholesterol metabolism is a druggable Axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer’s disease neurons. Cell Stem Cell. 2019;24(3):363-375.

[21] Zhang XW, Zhu XX, Tang DS, Lu JH. Targeting autophagy in Alzheimer’s disease: animal models and mechanisms. Zool Res. 2023;44(6):1132-1145.

[22] Essayan-Perez S, Sudhof TC. Neuronal gamma-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer’s disease. Neuron. 2023;111(20):3176-3194.

[23] van der Kant R, Goldstein L, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21-35.

[24] Xu J, Bankov G, Kim M, et al. Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer’s disease. Transl Neurodegener. 2020;9(1):36.

[25] Zhang X, Tong T, Chang A, et al. Midlife lipid and glucose levels are associated with Alzheimer’s disease. Alzheimers Dement. 2023;19(1):181-193.

[26] Liao F, Zhang TJ, Jiang H, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70.

[27] Victor MB, Leary N, Luna X, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell. 2022;29(8):1197-1212.

[28] Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381(10):903-911.

[29] Mody I. GABA(a)R modulator for postpartum depression. Cell. 2019;176(1-2):1.

[30] Birnie MT, Short AK, de Carvalho GB, et al. Stress-induced plasticity of a CRH/GABA projection disrupts reward behaviors in mice. Nat Commun. 2023;14(1):1088.

[31] Miller L, Campo JV. Depression in adolescents. N Engl J Med. 2021;385(5):445-449.

[32] Almulla AF, Thipakorn Y, Algon A, Tunvirachaisakul C, Al-Hakeim HK, Maes M. Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: a systematic review and meta-analysis. Brain Behav Immun. 2023;113:374-388.

[33] Shen Z, Sun D, Savastano A, et al. Multivalent tau/PSD-95 interactions arrest in vitro condensates and clusters mimicking the postsynaptic density. Nat Commun. 2023;14(1):6839.

[34] Ortiz-Sanz C, Balantzategi U, Quintela-Lopez T, et al. Amyloid beta/PKC-dependent alterations in NMDA receptor composition are detected in early stages of Alzheimer s disease. Cell Death Dis. 2022;13(3):253.

[35] Wang J, Gao F, Cui S, et al. Utility of 7, 8-dihydroxyflavone in preventing astrocytic and synaptic deficits in the hippocampus elicited by PTSD. Pharmacol Res. 2022;176:106079.

[36] Wang S, Sudan R, Peng V, et al. TREM2 drives microglia response to amyloid-beta via SYK-dependent and -independent pathways. Cell. 2022;185(22):4153-4169.

[37] Bai Y, Zhang X, Li Y, et al. Protein kinase a is a master regulator of physiological and pathological cardiac hypertrophy. Circ Res. 2024;134(4):393-410.

[38] Zhai P, Sciarretta S, Galeotti J, Volpe M, Sadoshima J. Differential roles of GSK-3beta during myocardial ischemia and ischemia/reperfusion. Circ Res. 2011;109(5):502-511.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.